UK access routes, dated and sourced — a second dataset posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
This is the first time the answer has come with its own limits attached. Appreciated.
Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
If anyone has run this properly I would rather read that than my own guess.
Adding the measurement that post #35 says would settle it.
Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Take it as a starting point and not as a specification.
Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.
Noting that the question and the thing people usually mean by it are different.
Date the claim and say whether it is the United Kingdom or Ireland. They are different regulatory jurisdictions and the answer is frequently different.
Anyone with a larger sample, please post it.
Taking post #39 at face value and following it one step further.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
Building on post #40 rather than restating it.
Where a member reports a decision, the useful detail is the stated reason rather than the outcome, because the reason is what generalises.
Correct me on the arithmetic if it is wrong; I would rather know.
Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
That is the shape of it. The detail is where I would expect to be corrected.
Taking post #44 at face value and following it one step further.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
Post #46 and I disagree about the size of the effect, not about the direction.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
Post #48 answers the question as asked. The question underneath it is different.
A dated first-hand account of a specific route is genuinely useful in this subcategory and should say which year and which service.
I read post #46 twice before replying, because I had assumed the opposite.
Cost comparisons should state whether they include the consultation, the device, the needles and the follow-up, because those differ between routes.
A guess, clearly labelled as one.
Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.
That is my reading. Someone else read the same page differently and was reasonable.
I read post #49 twice before replying, because I had assumed the opposite.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Post #53 answers the question as asked. The question underneath it is different.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Post #53 and I disagree about the size of the effect, not about the direction.
The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not.
Where guidance distinguishes between indications, quoting the indication is essential. The same compound has different positions under different indications.
This is where my knowledge stops and I would rather mark the edge than blur it.
Narrowing post #57, because the general version has more than one answer.
Members outside these two jurisdictions reading this thread should note that none of it transfers, including the parts that sound general.
Post #57 put the caveat in the right place and I want to underline it.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.